Episode
Episode 819: Cardiol Therapeutics ($CRDL): A New Approach to Treating Inflammation in Heart Disease
- Podcast
- Stocks To Watch
- Published
- May 19, 2026
- Duration seconds
- 854
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/stocks-to-watch-5696376/episodes/episode-819-cardiol-therapeutics-crdl-a-new-approach-to-treating-inflammation-in-heart-disease/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/stocks-to-watch-5696376/episode-819-cardiol-therapeutics-crdl-a-new-approach-to-treating-inflammation-in-heart-disease.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
This interview is disseminated on behalf of Cardiol Therapeutics Inc. In this episode of Stocks to Watch, we sit down with David Elsley, President and CEO of Cardiol Therapeutics (NASDAQ: CRDL | TSX: CRDL), to discuss the company's late-stage clinical development program targeting inflammation-driven heart conditions, including recurrent pericarditis and acute myocarditis. Learn more: https://www.cardiolrx.com Watch the full YouTube interview here: https://youtu.be/NXkzgfWHQnA And follow us to stay updated: https://www.youtube.com/GlobalOneMedia